IL2 and cancer: Indeed, such antibody/TCR chimera induced IL-2 release and cytolytic activity toward target cells in an MHC-independent fashion.41,42 The same research team redirected CTL hybridoma cells to cancer cells by a recombinant receptor that binds by the linked scFv antibody to the epidermal growth factor receptor (Her2/neu, ErbB2) overexpressed by a variety of cancers.43